Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T follicular helper cells contribute to pathophysiology in a model of neuromyelitis optica spectrum disorders
Leung-Wah Yick, Oscar Ka-Fai Ma, Ethel Yin-Ying Chan, Krystal Xiwing Yau, Jason Shing-Cheong Kwan, Koon-Ho Chan
Leung-Wah Yick, Oscar Ka-Fai Ma, Ethel Yin-Ying Chan, Krystal Xiwing Yau, Jason Shing-Cheong Kwan, Koon-Ho Chan
View: Text | PDF
Research Article Neuroscience

T follicular helper cells contribute to pathophysiology in a model of neuromyelitis optica spectrum disorders

  • Text
  • PDF
Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are inflammatory autoimmune disorders of the CNS. IgG autoantibodies targeting the aquaporin-4 water channel (AQP4-IgGs) are the pathogenic effector of NMOSD. Dysregulated T follicular helper (Tfh) cells have been implicated in loss of B cell tolerance in autoimmune diseases. The contribution of Tfh cells to disease activity and therapeutic potential of targeting these cells in NMOSD remain unclear. Here, we established an autoimmune model of NMOSD by immunizing mice against AQP4 via in vivo electroporation. After AQP4 immunization, mice displayed AQP4 autoantibodies in blood circulation, blood-brain barrier disruption, and IgG infiltration in spinal cord parenchyma. Moreover, AQP4 immunization induced motor impairments and NMOSD-like pathologies, including astrocytopathy, demyelination, axonal loss, and microglia activation. These were associated with increased splenic Tfh, Th1, and Th17 cells; memory B cells; and plasma cells. Aqp4-deficient mice did not display motor impairments and NMOSD-like pathologies after AQP4 immunization. Importantly, abrogating ICOS/ICOS-L signaling using anti–ICOS-L antibody depleted Tfh cells and suppressed the response of Th1 and Th17 cells, memory B cells, and plasma cells in AQP4-immunized mice. These findings were associated with ameliorated motor impairments and spinal cord pathologies. This study suggests a role of Tfh cells in the pathophysiology of NMOSD in a mouse model with AQP4 autoimmunity and provides an animal model for investigating the immunological mechanisms underlying AQP4 autoimmunity and developing therapeutic interventions targeting autoimmune reactions in NMOSD.

Authors

Leung-Wah Yick, Oscar Ka-Fai Ma, Ethel Yin-Ying Chan, Krystal Xiwing Yau, Jason Shing-Cheong Kwan, Koon-Ho Chan

×

Figure 2

AQP4 immunization generates AQP4 autoantibodies.

Options: View larger image (or click on image) Download as PowerPoint
AQP4 immunization generates AQP4 autoantibodies.
(A) Detection of AQP4 a...
(A) Detection of AQP4 autoantibodies in mouse serum by cell-based indirect immunofluorescence assay. HEK293 cells were transfected with a plasmid encoding the mouse AQP4 M23 isoform. AQP4 autoantibodies in the serum were visualized by fluorescence-conjugated secondary antibody specific for mouse IgG. Top left: Immunostaining with commercial anti-AQP4 antibody revealed a discontinuous pattern of AQP4 staining on the cell membrane (positive control). Top middle and right: No AQP4 immunoreactivity was observed when commercial anti-AQP4 antibody was absent or HEK293 cells were not transfected (negative controls). Bottom: Immunostaining of transfected HEK293 cells using the serum of naive, pEmpty(C/P+), pAQP4(C/P–), and pAQP4(C/P+) mice. Nuclei were counterstained with DAPI. Images are representative of 8 mice per group. Scale bar: 50 μm. Original magnification, ×400 (insets). (B) Titer of AQP4 autoantibodies was measured by ELISA using serial dilution of serum from 1:10 to 1:10,000. (C) Concentration of AQP4 autoantibodies was determined using serum diluted at 1:1,000. (D) Spinal cord sections of WT and Aqp4-deficient (Aqp4–/–) mice were immunostained using the serum of pEmpty(C/P+) and pAQP4(C/P+) mice. Images are representative of 3 mice per group. Data are mean ± SEM; n = 3 per group. ***P < 0.001, 1-way ANOVA with post hoc Tukey’s test. Scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts